1 Correction to: Targeted Oncology (2020) 15:599–611 https://doi.org/10.1007/s11523-020-00748-4

Page 608, 4 Discussion, right column, second paragraph: The sentence, which previously read:


“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 0.3 to 11.2%)”.


should read:


“Equivalence in clinical efficacy of ABP 798 with respect to rituximab RP in patients with CD20-positive B-cell NHL was further supported by the results of efficacy assessment at week 12, with a two-sided 90% CI (− 9.3 to 11.2%)”.

The original article has been updated.